On November 28, 2024, Hansoh Pharmaceutical Group Company Limited announced that the following four innovative drugs of the Group had been renewed inthe National Reimbursement Drug List (2024 Version) (the “2024 NRDL”) published by China’s National Healthcare Security Administration and the Ministry of Human Resources and Social Security. The 2024 NRDL will be officially implemented on January 1, 2025.

1. Aumolertinib Mesilate Tablets (trade name: Ameile阿美乐^®) is the first domestic innovative third-generation epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) drug independently developed by Hansoh, and its two approved indications have been renewed in the 2024 NRDL:

•The first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors have EGFR exon 19 deletions or exon 21(L858R) substitute mutation.

•The treatment of locally advanced or metastatic NSCLC in adult patients who have progressed on or after EGFR-TKI therapy, and have been confirmed to have EGFR T790M mutation positivity through testing.

2. Flumatinib Mesylate Tablets (trade name: Hansoh Xinfu豪森昕福^®) is China’ s first domestic innovative second-generation Bcr-Abl TKI drug independently developed by Hansoh, and is used to treat adult patients with Philadelphia chromosome positive chronic myelogenous leukemia (Ph+CML) in the chronic phase.

3. Inebilizumab Injection (trade name: XINYUE昕越^®) is a targeted CD19 B-cell depleting antibody for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are AQP4 antibody-positive.

4. PEG-Loxenatide for Injection (trade name: Fulaimei孚来美^®) is the first innovative drug derived from Hansoh’s proprietary PEGylation technology, it is China’s first domestic innovative GLP-1RA weekly dosage form formulation, used for patients with BMI ≥ 25 who have poor oral hypoglycemic drugs such as metformin or insulin control effects.

Additionally, the innovative drugs Pegmolesatide Injection (trade name: Saint Luolai圣罗莱^®) and Tenofovir Amibufenamide Tablets (trade name: Hengmu恒沐^®) were included in the 2023 NRDL and they are currently within the agreement period, with the agreement valid until December 31, 2025; Morinidazole Sodium Chloride for Injection (trade name: Mailingda迈灵达^®) has been included in category B of general list of the NRDL. All indications for the innovative drugs launched by Hansoh are included in the NRDL, which helps to further improve the affordability and accessibility of the innovative drugs among patients.